Results 111 to 120 of about 69,008 (285)

Postexercise muscle oxygen uptake kinetics in older breast cancer survivors and healthy individuals: Association with myosteatosis

Experimental Physiology, EarlyView.
Abstract Reduced cardiorespiratory fitness is common among breast cancer survivors and, although traditionally attributed to cardiac dysfunction, might also be related to peripheral skeletal muscle abnormalities. We examined peak and submaximal plantar‐flexion exercise and recovery kinetics for lower‐leg oxygen uptake (V̇O2${\dot V_{{{\mathrm{O}}_2}}}$)
Nathan R. Weeldreyer, Thomas J. McMurtry, Stephen J. Foulkes, Amanda Shewman, Edith Pituskin, Rachel J. Skow, Richard B. Thompson, Justin Grenier, Deirdre E. O'Neill, Robert C. Welsh, Mark J. Haykowsky, Corey R. Tomczak   +11 more
wiley   +1 more source

A Case of Human Epidermal Growth Factor Receptor 2‐Positive Colon Cancer With Invasive Micropapillary Carcinoma Component

DEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT A female patient in her 60s tested positive for the fecal occult blood test while undergoing health screening. Colonoscopy revealed a 15‐mm‐sized flat elevated lesion with a central depression in the sigmoid colon. Narrow‐band imaging magnification revealed a Japan Narrow‐Band Imaging Expert Team classification of type 2B, whereas crystal ...
Masashi Kono, Yoriaki Komeda, Hiroshi Kashida, Satoru Hagiwara, Akihiro Yoshida, Shunsuke Omoto, Mamoru Takenaka, Naoko Tsuji, George Tribonias, Masatoshi Kudo   +9 more
wiley   +1 more source

Endoscopic Complete Response to Zolbetuximab for Advanced Gastric Cancer With Claudin 18.2 Positive: A Case Report

DEN Open, Volume 6, Issue 1, April 2026.
ABSTRACT Recently, zolbetuximab combined with chemotherapy has been approved as a first‐line treatment for advanced gastric cancer (GC). However, to date, no endoscopic images demonstrating endoscopic complete response (eCR) to zolbetuximab plus chemotherapy have been reported.
Akinori Sasaki, Tomohiro Yamaba, Ayu Tachibana, Rika Kimura, Gaku Uchiyama, Tsubasa Yoshioka, Risa Okamoto   +6 more
wiley   +1 more source

Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis [PDF]

, 2018
Florence R. Wilson, Megan Coombes, Christine Brezden‐Masley, Mariya Yurchenko, Quinlan Wylie, Reuben Douma, Abhishek Varu, Brian Hutton, Becky Skidmore, Chris Cameron   +9 more
openalex   +1 more source

Delivering precision oncology in metastatic breast cancer: Clinical impact of comprehensive genomic profiling—The CATCH experience

International Journal of Cancer, Volume 158, Issue 6, Page 1675-1689, 15 March 2026.
What's new? CATCH is a prospective precision oncology registry trial that harnesses whole‐genome/exome‐ and RNA‐sequencing to enable actionable biomarker detection in metastatic breast cancer patients of any subtype. The data of the first 412 consecutive patients with completed follow‐up in this real‐world, single‐center patient cohort provide robust ...
Mario Hlevnjak, Sabine Heublein, Verena Thewes, Lukas Wagener, Constantin Pixberg, Carlo Fremd, Laura Michel, Christian Maurer, Lars Buschhorn, Nicola Dikow, Fangyoumin Feng, Stefan Fröhling, Christel Herold‐Mende, Steffen Hirsch, Chen Hong, Daniel Hübschmann, Lena Jassowicz, Polina Kozyulina, Katrin Pfütze, Richard F. Schlenk, Hans‐Peter Sinn, Katharina Smetanay, Christoph Springfeld, Albrecht Stenzinger, Celina Wagner, Stephan Wolf, Andreas Trumpp, Dirk Jäger, Oliver Zivanovic, Marc Zapatka, Andreas Schneeweiss, Peter Lichter   +31 more
wiley   +1 more source

Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice [PDF]

Giulia Notini, Matteo Maria Naldini, Lorenzo Sica, Giulia Viale, Alessia Rognone, Stefania Zambelli, Patrizia Zucchinelli, Marta Piras, Carlo Bosi, Marco Giovanni Mariani, D. Aldrighetti, Giampaolo Bianchini, Luca Licata   +12 more
openalex   +1 more source

Supplementary appendix from Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers

, 2023
Solange Peters, Rolf A. Stahel, Lukas Bubendorf, Philip Bonomi, Augusto Villegas, Dariusz M. Kowalski, Christina S. Baik, Dolores Isla, Javier de Castro, Pilar Garrido, Achim Rittmeyer, Marcello Tiseo, Christoph Meyenberg, Sanne de Haas, Lisa H. Lam, Michael W. Lu, Thomas E. Stinchcombe   +16 more
openalex   +1 more source

147P Pharmacokinetics, safety, and efficacy of trastuzumab deruxtecan (T-DXd) with OATP1B/CYP3A inhibitors in patients with HER2-expressing advanced solid tumours [PDF]

, 2020
Masato Takahashi, Y-J. Bang, Masato Karayama, Junichiro Watanabe, Hironobu Minami, Noboru Yamamoto, Ichiro Kinoshita, C.-C. Lin, Y-H Im, T Fujiki, Issei Achiwa, Emi Kamiyama, Yasuyuki Okuda, C. Lee, Shunji Takahashi   +14 more
openalex   +1 more source

Evaluating distant recurrence‐free survival and location of metastasis in HER2+ breast cancer by ER status

International Journal of Cancer, Volume 158, Issue 5, Page 1184-1192, 1 March 2026.
What's New? The prognostic significance of the presence or absence of human epidermal growth factor receptor 2 (HER2) and estrogen receptor (ER) in breast cancer is well‐established. However, the relationship of HER2 and ER with distant disease recurrence and metastasis location is less well understood.
Damien Kaukonen, Alexander Ploner, Erwei Zeng, Jenny Bergqvist, Kamila Czene   +4 more
wiley   +1 more source

Supplementary Figure 2 from Long-Term Survival Analysis of Adjuvant Chemotherapy with or without Trastuzumab in Patients with T1, Node-Negative HER2-Positive Breast Cancer

, 2023
Xuexin He, Jiali Ji, Mei Tian, Francisco J. Esteva, Gabriel N. Hortobágyi, Sai‐Ching J. Yeung   +5 more
openalex   +1 more source